Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Change in Acquisitions & Divestments: 2019-2025

Historic Change in Acquisitions & Divestments for KalVista Pharmaceuticals (KALV) over the last 7 years, with Apr 2025 value amounting to $122.5 million.

  • KalVista Pharmaceuticals' Change in Acquisitions & Divestments rose 30.56% to $20.2 million in Q2 2025 from the same period last year, while for Apr 2025 it was $122.8 million, marking a year-over-year increase of 17.00%. This contributed to the annual value of $122.5 million for FY2025, which is 16.74% up from last year.
  • As of FY2025, KalVista Pharmaceuticals' Change in Acquisitions & Divestments stood at $122.5 million, which was up 16.74% from $105.0 million recorded in FY2024.
  • KalVista Pharmaceuticals' 5-year Change in Acquisitions & Divestments high stood at $195.7 million for FY2022, and its period low was $53.6 million during FY2021.
  • For the 3-year period, KalVista Pharmaceuticals' Change in Acquisitions & Divestments averaged around $122.8 million, with its median value being $122.5 million (2025).
  • In the last 5 years, KalVista Pharmaceuticals' Change in Acquisitions & Divestments skyrocketed by 264.87% in 2022 and then dropped by 28.03% in 2023.
  • KalVista Pharmaceuticals' Change in Acquisitions & Divestments (Yearly) stood at $53.6 million in 2021, then soared by 264.87% to $195.7 million in 2022, then declined by 28.03% to $140.9 million in 2023, then decreased by 25.49% to $105.0 million in 2024, then climbed by 16.74% to $122.5 million in 2025.